The global, multicenter, randomized, open-label study enrolled 501 treatment-naive patients with locally advanced or metastatic and/or unresectable HCC and randomized them 2:1 to 1200 mg of intravenous (IV) atezolizumab every 3 weeks plus 15 mg/kg of IV bevacizumab every 3 weeks (n = 336) ...
根据IMbrave150期研究(NCT03434379),在肝细胞癌(HCC)患者中,与索拉非尼相比,阿索唑单抗和贝伐单抗的一线组合在统计学上和临床上均改善了无进展生存期(PFS)和总体生存期(OS)来自罗氏。 使用atezolizumab / bevacizumab可使HCC患者的死亡风险降低42%(HR,0.58; 95%CI,0.42-0.79; P = 0.0006),PFS率为41%(HR,0.59...
Atezolizumab /贝伐珠单抗 Bevacizumab用于晚期或不可切除的HCC 欧盟委员会已批准将atezolizumab(Tecentriq)加上bevacizumab(Avastin)的组合用于尚未接受过全身治疗的晚期或不可切除肝细胞癌(HCC)的成年患者。 据罗氏公司称,获得这一批准后,阿泰珠单抗/贝伐单抗是欧洲第一个获得批准的不可切除肝癌患者的免疫疗法。 该决定基...
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.
EP: 2.Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCCStacey Stein, MD, associate professor of internal medicine at the Yale School of Medicine and assistant medical director of the clinical trials office at Yale Cancer Center, discusses the patient population and outcomes of...
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated comparable clinical activity and safety versus sorafenib (Nexavar) in older and younger patients with previously untreated, unresectable hepatocellular carcinoma (HCC), according to findings from exploratory subgroup analy...
Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study - ScienceDirectdoi:10.1093/annonc/mdy432.002K.-H. LeeC.-H. HsuM.S. LeeB.-Y. RyooW. VerretA.R. HeA. KwanB. Liu...
Used in combination to treat Unresectable hepatocellular carcinoma (hcc) Regimen in combination with: Bevacizumab (DB00112) •••••••••••• ••••• ••••••••• ••••• Used in combination to treat Unresectable melanoma Regim...
Hepatocellular Carcinoma (HCC)Used in combination with bevacizumab for the treatment of patients with unresectable or metastatic HCC (designated an orphan drug by FDA for treatment of this cancer).MelanomaUsed in combination with cobimetinib and vemurafenib for the treatment of unresectable or metastatic...
德国协会肝病研究学会的Peter R.加勒,医学博士,医学部的大学医学中心的美因茨导演,并当选总统,讨论了从第三阶段IMbrave 150临床试验,评估出来的结果Atezolizumab(Tecentriq)加上bevacizumab(Avastin)与标准治疗方法索拉非尼(Nexavar)的组合作为不可切除的肝细胞癌(HCC)患者的一线治疗。